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Background:Small-cell lung cancer (SCLC), a variant of lung cancer marked by early metas-
tases, accounts for 13% of all lung cancers diagnosed in US. Despite high response rates
to treatment, it is an aggressive disease with a median survival of 9–11 months for patients
with extensive stage (EX-SCLC). Detection of circulating tumor cells (CTCs) is a novel labo-
ratory technique currently in use to determine response to therapy and to predict prognosis
in breast, colorectal, and prostate cancer. We initiated a pilot study to analyze the role of
CTCs as a biomarker of response and relapse in patients with EX-SCLC.
Methods: We collected blood samples from chemotherapy naïve patients with EX-SCLC
prior to initiation of therapy, after completion of systemic therapy, and follow-up every 6–
8 weeks and at relapse.The number of CTCs was determined using the cell search system
in a central laboratory.The study was conducted in four different sites, and it was reviewed
and approved by respective research review committees and IRBs.
Results:We enrolled 26 patients with EX-SCLC, 1 was excluded due to ineligibility, all were
treated with platinum and etoposide. We observed partial response in 16 patients, stable
disease in 3 patients, 1 patient with disease progression, and 6 patients were not assessed
(5 deceased, 1 not available).The overall median number of CTCs in 24 patients measured
at baseline and post-tx was 75 (range 0–3430) and 2 (range 0–526), respectively. A signifi-
cant reduction in CTCs from baseline to post-treatment was identified for 15 subjects; the
median reduction was 97.4% (range −100 to +100%, p<0.001). Higher baseline CTCs
and percentage change in post-treatment CTCs were associated with decreased survival.
Conclusion: We demonstrated that it is feasible to detect CTCs in EX-SCLC. If validated
in other prospective studies, CTCs could be a useful biomarker in the management of
EX-SCLC by predicting patients’ clinical responses to therapy.
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INTRODUCTION
Lung cancer is the leading cause of cancer death among men and
women in the United States (1). Small-cell lung cancer (SCLC) is a
variant of lung cancer marked by early metastases, and it accounts
for 13% of all lung cancers diagnosed in the United States. At the
time of presentation, two-thirds of patients will have disseminated
disease making systemic chemotherapy the cornerstone of treat-
ment. Sixty to eighty percent of patients with SCLC achieve an
objective response with combination chemotherapy but despite
these high responses, it is an aggressive disease with a median
survival of 9–11 months for patients with extensive stage disease
(EX-SCLC) (2). Clinical research efforts to improve the treatment
for SCLC have been unsuccessful. Cisplatin or carboplatin and
etoposide have been the treatment of choice for over 20 years
(3). While we continue to pursue novel therapies for this dis-
ease, it is imperative that we concurrently pursue other strategies
such as biomarker development to accurately monitor therapeutic
responses, detect early progression, and predict clinical outcomes.
Biomarkers are powerful tools to help us further understand the
complex biology of cancer and to determine clinical responses in
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patients. Currently, there are no validated biomarkers to follow
the disease activity in SCLC. Detection of circulating tumor cells
(CTCs) is a novel laboratory technique currently in use to deter-
mine response to therapy and to predict prognosis in breast (4),
colorectal (5), and prostate cancer (6). It is also present in lung
cancer patients.
We hypothesize that CTCs will be a valuable and versatile
biomarker for therapeutic response, determination of relapse,
and survival in patients with SCLC. We conducted a study to
determine if CTCs are a viable blood biomarker for survival,
response, and relapse. We isolated and characterized CTCs using
the CELLSEARCH®. This system is able to detect ≥2 CTCs
in 36% of the 964 malignant samples compared to one (0.3%)
of the 199 non-malignant samples and none of the 145 healthy
controls (7).
The primary objective was to determine the number of CTCs in
patients with EX-SCLC prior to initiation of chemotherapy, after
therapy, and at time of relapse.
MATERIALS AND METHODS
CTC DETECTION
Patients were recruited from four participating sites: University
of Kansas Medical Center, Kansas City VA, USA, University of
Nebraska, and Omaha, VA, USA; the study was reviewed and
approved by IRB of participating institutions. Eligible patients
had a histological diagnosis of EX-SCLC and were planned to
start chemotherapy. We collected blood samples for CTC detec-
tion before chemotherapy and within 4 weeks after treatment. The
samples were collected from Monday to Wednesday in order to
have time for processing. The CTC detection was performed cen-
trally at University of Kansas Medical Center. We also obtained
blood samples every 6–8 weeks during follow-up and at time of
progression.
Sample preparation for isolation of epithelial cells from blood
was done by collecting 7.5 mL of blood collected in special Veridex
instrument tubes and mixed with 6.5 mL of buffer, centrifuged
at 800× g for 10 min, and then placed on the CellPrep system.
After aspiration of the plasma and buffer layer by the instrument,
ferrofluids were added, which were coated with epithelial cell-
specific EpCAM antibodies that immunomagnetically isolated the
epithelial cells from the patient sample (8). After the incuba-
tion period and subsequent magnetic separation, unbound cells
and remaining plasma were aspirated and discarded. The staining
reagents were then added in conjunction with a permeabiliza-
tion buffer to fluorescently label the immunomagnetically isolated
epithelial CTCs. After incubation on the system, the magnetic sep-
aration was repeated, and excess staining reagents were aspirated
and discarded. In the final processing step, the cells were resus-
pended in the MagNest cell presentation device (Veridex LLC).
This device consists of a chamber and two magnets that orient the
immunomagnetically isolated and stained cells for analysis using
the CellSpotter Analyzer.
SAMPLE ANALYSIS
The MagNest is placed on the CellSpotter Analyzer, a four-color
semiautomated fluorescence microscope. Image frames covering
the entire surface of the cartridge for each of the four fluorescent
filter cubes are captured. The captured images containing objects
that meet pre-determined criteria are automatically presented in
a web-enhanced browser from which the final selection of cells is
made by the operator. The criteria for an object to be defined as a
CTC includes round to oval morphology, a visible nucleus (DAPI
positive), positive staining for cytokeratin, and negative staining
for CD45 (9, 10). Results of cell enumeration are always expressed
as the number of cells per 7.5 mL of blood.
STATISTICAL CONSIDERATIONS
This study was strictly exploratory and descriptive in nature.
We intended to use the data to develop a larger, confirmatory
study examining the association between CTC levels and survival,
response, and relapse. The information in this study was to assist
in deriving cutoff values for clinically meaningful differences in
CTC levels from baseline to response and to relapse.
DETERMINATION OF SAMPLE SIZE
Sample size calculations were based on a two-sided 95% confi-
dence interval estimating the average drop in CTC levels from
baseline to post-two cycles of treatment. For n= 25, a two-sided
95% confidence interval for the change would have an interval
that extends no more than 0.916 from the observed difference
in means with 80% coverage probability, assuming that the true
standard deviation of differences is σd= 2 and that the confidence
interval was based on the Student’s t statistic. To accommodate the
possibility of dropout or samples that are not viable, an additional
four (15%) subjects were enrolled, for a total sample size of n= 29.
We anticipated the proportion of subjects who would respond to
be 0.65.
RESULTS
We enrolled a total of 26 patients; one patient was not eligible
because the patient had limited stage SCLC, for a total of 25 includ-
ing 19 males (76%) and 6 females. The median age was 63 years old
(range 50–79). All patients had extensive stage SCLC. The median
pre-treatment CTC count was 75 (range 0–3430), and the median
post-treatment CTC was 1 (range 0–526). Sixteen patients (61.5%)
responded to therapy, 3 (11.5%) had stable disease, 1 (3.9%) expe-
rienced disease progression, and 6 (23.1%) patients did not have
disease assessment.
Baseline characteristics of subjects were summarized using
means and standard deviations for continuous variables; medians
and ranges for continuous variables with skewness or outliers; and
frequencies and percentages for categorical variables (Table 1).
CTCs were summarized at baseline and at four post-treatment
measurements using medians and ranges (Table 2). A description
of the number of days lapsed between pre-treatment and each
post-treatment measure is also provided. Percent change in CTCs
from baseline was calculated as 100*(post – pre)/pre, and was sum-
marized using medians and ranges. Non-parametric sign tests were
used to test for significant decreases in CTCs from baseline levels
(Table 2). Best response was summarized using frequencies and
percentages. Overall survival (OS) was calculated as the number
of subjects surviving at the end of the study period over the total
number of study subjects. Kaplan–Meier product-limit estimates
of survival were computed, and duration of survival was calcu-
lated as the time between baseline (pre-treatment) and date of
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Table 1 | Baseline characteristics.
KCVA (n=12) KUCC (n=7) OMVA (n=5) UNMC (n=2) All Subjects (n=26)
Age (mean, SD in years)a 62.6 (8.3) 60.8 (6.9) 68 (5.7) 70 (6.7) 63.8 (7.6)
Male Gender (n, %)b 11 (91.7) 2 (33.3) 5 (100) 1 (50) 19 (76)
CTCs (median, range)c 56 (0, 2835) 28 (1, 313) 257 (0, 1924) 1786.5 (143, 3430) 75 (0, 3430)
aAge missing for one KUCC subject.
bGender missing for one KUCC subject.
cBaseline CTCs missing for two subjects (KCVA and KUCC).
Table 2 | Circulating tumor cells detection.
N Days since baselinea CTCsa % Change from baselinea pb
Baseline 24 0 75 (0, 3430) – –
Post-Tx (1) 16 133 (69, 183) 1 (0, 526) −98.7 (−100, 100) <0.001
Post-Tx (2) 6 209.5 (177, 236) 7.5 (0, 1679) −86.1 (−100, 2898) 0.7
Post-Tx (3) 2 266 (231, 301) 0.5 (0, 1) −50 (−100, 0) 0.9
Post-Tx (4) 1 315 (–) 4 (–) 0 (–) –
aMedian (minimum, maximum) reported.
bp-value is based on the non-parametric Sign test looking for a significant decrease from baseline levels.
Table 3 | Response evaluation.
KCVA (n=12) KUCC (n=7) OMVA (n=5) UNMC (n=2) All subjects
Evaluable for response (n %) 9 (75) 5 (71.4) 5 (100) 1 (50) 20 (76.9)
Overall survival (n %) 0 (0) 3 (42.9) 1 (25) 0 (0) 4 (15.4)
Duration of survival (median, range in days)a 197 (14, 391) 252 (58, 385) 258.5 (185, 390) 201 (89, 313) 215 (14, 391)
RESPONSE
Partial response (n %) 8 (66.7) 5 (71.4) 2 (40) 1 (50) 16 (61.5)
Stable disease (n %) 0 (0) 0 (0) 3 (60) 0 (0) 3 (11.5)
Progressive disease (n %) 1 (8.3) 0 (0) 0 (0) 0 (0) 1 (3.9)
Not evaluable (n %) 3 (25) 2 (28.6) 0 (0) 1 (50) 6 (23.1)
Recurrence-free survival (median, range in days)b 215 (66, 362) 273 (145, 497) – – 278 (147, 385)
aPre-treatment measurement to date of death, two censored subjects.
bPre-treatment measurement to date of recurrence, three censored subjects.
Table 4 | Maximum likelihood estimates (standard errors) and hazard
ratios from cox proportional hazards regression model including the
predictors baseline CTCs and % change from baseline to
post-treatment.
MLE (SE) χ2 (p) HR
Baseline CTCs 0.025 (0.012) 4.4 (0.036) 1.025
% Change in CTCs 0.027 (0.016) 2.8 (0.09) 1.028
death. Recurrence-free survival was calculated as the time between
baseline (pre-treatment) and date of disease recurrence (Table 3).
To test for an association between CTC levels and prognosis, we
used Cox proportional hazards regression. The model included the
covariates: baseline CTCs, percent-change in CTCs from baseline
to post-treatment, and age (Table 4).
Twenty-four subjects had information on CTCs at baseline and
16 had at least one follow-up measurement post-treatment. The
median number of days elapsed from baseline to post-treatment
assessment was 135 (range 69–183 days). The median number of
CTCs measured at baseline and post-treatment was 75 (range 0–
3430) and 2 (range 0–526), respectively. A significant reduction in
CTCs from baseline to post-treatment was identified for 16 sub-
jects, the median reduction was 98.7% (range −100 to +100%,
p< 0.001). A non-parametric sign test was used due to the small
sample size and assumption violations of the parametric t -test. A
plot of the individual patient data is provided in Figure 1.
Kaplan–Meier survival estimates of subjects who showed par-
tial response, stable disease, progressive disease, and those not
evaluable for response due to early death are displayed in Figure 2.
Significant differences in survival were found (log-rank χ2= 8.9,
p= 0.03). Partial responders survived, on average, 315 days (95%
CI: 207, 385). Subjects with stable disease had median survival
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FIGURE 1 | Plot of individual patient-level CTC change data (log scale). The x -axis is number of days post-treatment at which the CTC measurement was
collected for patient, y -axis is the percent change from baseline at that time for each patient, each patient has a line representing his or her change.
FIGURE 2 | Kaplan–Meier survival estimates of subjects who showed
partial response (green, n=12, two censored), progressive disease (red,
n=1), and those not evaluable for response due to early death (blue,
n=5). Three subjects with stable disease are not shown due to missing
survival data. Significant differences in survival were found (log-rank χ2 =25.3,
p<0.0001). Partial responders survived, on average, 321 days (95% CI: 189,
385). Subject with progressive disease survived 38 days. Subjects not
evaluated for response had median survival of 65 days (95% CI: 14, 89).
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FIGURE 3 | Kaplan–Meier survival estimates of subjects with measurable
CTCs at baseline (>5, red, n= 17, one censored) and without (<5. blue,
n=9, three censored). Subjects with >5 CTCs at baseline survived, on
average, 223 days (95% CI: 65, 321). Subjects with <5 CTCs at baseline had
median survival of 358 days (95% CI: 58, 358). Differences in survival were
significant at the 10% level (log-rank χ2 =1.99, p=0.1).
of 268 days (95% CI: 185, 390). Subject with progressive disease
survived 38 days. Subjects not evaluated for response had median
survival of 74.5 days (95% CI: 14, 84).
Likewise, survival for subjects with fewer than five CTCs at base-
line was compared with those with at least five CTCs (Figure 3).
Subjects with ≥5 CTCs at baseline survived, on average, 223 days
(95% CI: 65, 321). Subjects with <5 CTCs at baseline had
median survival of 358 days (95% CI: 58, 358). Differences in
survival were significant at the 10% level (log-rank χ2= 1.99,
p= 0.1).
Baseline CTCs (χ2= 4.4, p= 0.036) and % change in CTCs
from baseline to post-treatment (χ2= 2.8, p= 0.09) was not sta-
tistically significant associated with survival but trended toward
significance. Age was also not associated with survival (p> 0.1).
On average, hazard ratios indicate the risk of death increases by
2.5% for every unit increase in CTCs at baseline, and by 2.8% on
average for every unit increase in % change, that is, an increase of
10 CTCs at baseline is associated with a 25% increase in the risk
of death (Table 4).
Receiver operating characteristic (ROC) curves for classifying
survival as a function of baseline CTCs and pre- to post-treatment
changes in CTCs are shown in Figure 4. AUC for baseline CTCs
and change in CTCs are 0.731 (95% CI: 0.36, 1.0) and 0.68 (95%
CI: 0.33, 1.0), respectively.
DISCUSSION
The presence of CTCs in the blood has been studied as a prognos-
tic biomarker in several types of cancer. Cristofanilli et al. showed
that CTCs are predictive of progression-free survival (PFS) and OS
in 177 patients with metastatic breast cancer. Patients with levels of
CTC ≥5 cells compared with patients with <5 CTCs had shorter
median PFS (2.7 vs. 7 months, p< 0.001) and shorter OS (10.1 vs.
18 months p< 0.001). Patients with high versus low numbers of
CTCs collected after the initiation of therapy had a PFS of 2.1 vs.
7 months (p≤ 0.001) and OS of 8.1 vs.>18 months (p< 0.001) in
their respective groups (4). CTCs have also been explored as pre-
dictors of treatment efficacy. Eighty-three untreated patients with
metastatic breast cancer had their blood analyzed for detection of
CTCs before treatment and then monthly for 6 months. Patients
with ≥5 CTCs at baseline and at first follow-up (4 weeks) had
a worse prognosis than patients with <5 CTCs. At baseline, the
median PFS 4.9 vs. 9.5 months (p= 0.0014) and the median sur-
vival(S) was 14.2 vs.>18 months (p= 0.0048), respectively. At first
follow-up, the median PFS was 2.1 vs. 8.9 months (p= 0.007) and
median OS of 11.1 vs.>18 months (p= 0.0029), respectively (11).
Similarly, studies in prostate cancer have looked at CTCs as a
prognostic marker in metastatic castration-resistant prostate can-
cer (CRPC) (6). At baseline,≥5 CTCs corresponded to worsened
median OS (21.7 vs. 11.5 months, p< 0.0001) in 231 patients.
Patients with≥5 CTCs 2–5 weeks after the initiation of treatment
had a median OS 9.5 months, compared to a median OS of
20.7 months in patients with <5 CTCs. CTC counts predicted
OS better than PSA decrement algorithms at all time points
(p= 0.0218) (6).
The prognostic significance of utilizing CTCs was also demon-
strated in metastatic colorectal patients. Cohen et al. studied
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FIGURE 4 | Receiver operating characteristic (ROC) curves for CTCs at
baseline (red, AUC=0.7308, 95% CI: 0.36, 1.0) and change in CTCs from
pre- to post-treatment (blue, AUC=0.6795, 95% CI: 0.33, 1.0).
presence of CTCs in 430 patients with mCRC at baseline and after
starting first, second, or third line therapy. Patients were stratified
into unfavorable and favorable prognostic groups based on CTC
levels of ≥3 or <3 CTCs/7.5 mL, respectively. The unfavorable
group had shorter median PFS (4.5 vs. 7.9 months; p= 0.0002)
and OS (9.4 vs. 18.5 months; p< 0.0001) compared with favor-
able group (5). Based on these studies, the cell search system has
been approved by FDA to predict PFS and OS in patients with
metastatic breast cancer and monitoring of metastatic colorectal
cancer and CRCP.
Similar to the results above, several reports in the literature
along with our study showed that CTCs decreased in response
to chemotherapy in SCLC supporting the use of CTCs as a bio-
marker for response. Naito et al. studied the presence of CTCs in
patients with SCLC. There were 35 patients with detectable two or
more baseline CTCs. Patients with ≥8 CTC levels at baseline had
worse prognosis compared to patients with <8 CTC at baseline
(p= 0.0014). Also, post-treatment CTCs ≥8 also had worse out-
comes compared to<8. The study demonstrated that higher CTC
count is associated with worse prognosis and it can be a valuable
prognostic marker (12). A similar study by Hou et al. showed that
CTCs were detectable in 77 of 97 patients. The study showed that
pre-treatment CTC counts decrease after one cycle of chemother-
apy, which is an independent prognostic factor. The OS was longer
in patients with CTCs <50 compared to patients with CTC ≥50,
11.5 vs. 5.4 months, respectively (p< 0.0001) (13).
Our study only showed a trend between higher CTCs and
percentage of change in post-treatment CTCs with worse out-
come. This is probably because higher levels of CTCs at baseline
would probably indicate a higher disease burden, and the degree
of change of CTCs from baseline would probably indicate the effi-
cacy of therapy. Our study is limited by the small sample size. A
larger study is needed to confirm the link between the change of
CTC and outcome.
Circulating tumor cells could potentially serve as a surrogate
to the primary tumor. The future of utilizing CTCs would be
greatly enhanced with genomic analysis of CTCs. The more we
learn about CTCs, the more likely we will be able to use them in
making bedside treatment decisions.
CONCLUSION
The identification of CTCs in blood samples of patients with EX-
SCLC is feasible in this multi-institutional pilot study. A larger trial
is necessary to study its prognostic significance. It is possible that in
the future, CTCs will be incorporated in the management of SCLC
and be used to monitor early recurrence. This could allow us to
make treatment decisions before there is evidence of radiographic
disease in order to help suppress clinical progression which could
lead to extended survival.
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